Literature DB >> 21220488

Glutathione-conjugate transport by RLIP76 is required for clathrin-dependent endocytosis and chemical carcinogenesis.

Sharad S Singhal1, Dilki Wickramarachchi, Sushma Yadav, Jyotsana Singhal, Kathryn Leake, Rit Vatsyayan, Pankaj Chaudhary, Poorna Lelsani, Sumihiro Suzuki, Shaohua Yang, Yogesh C Awasthi, Sanjay Awasthi.   

Abstract

Targeted depletion of the RALBP1-encoded 76-kDa splice variant, RLIP76, causes marked and sustained regression of human xenografts of lung, colon, prostate, and kidney cancers without toxicity in nude mouse models. We proposed that the remarkable efficacy and broad spectrum of RLIP76-targeted therapy is because its glutathione-conjugate (GS-E) transport activity is required for clathrin-dependent endocytosis (CDE), which regulates all ligand-receptor signaling, and that RLIP76 is required not only for survival of cancer cells but also for their very existence. We studied RLIP76 mutant proteins and the functional consequences of their expression into RLIP76(-/-) MEFs, identified key residues for GS-E binding in RLIP76, established the requirement of RLIP76-mediated GS-E transport for CDE, and showed a direct correlation between GS-E transport activities with CDE. Depletion of RLIP76 nearly completely blocked signaling downstream of EGF in a CDE-dependent manner and Wnt5a signaling in a CDE-independent manner. The seminal prediction of this hypothesis-RLIP76(-/-) mice will be deficient in chemical neoplasia-was confirmed. Benzo[a]pyrene, dimethylbenzanthracene, and phorbol esters are ineffective in causing neoplasia in RLIP76(-/-). PMA-induced skin carcinogenesis in RLIP76(+/+) mouse was suppressed completely by depletion of either PKCα or RLIP76 by siRNA or antisense and could be restored by topical application of RLIP76 protein in RLIP76(-/-) mouse skin. Likewise, chemical pulmonary carcinogenesis was absent in female and nearly absent in male RLIP76(-/-) mice. In RLIP76(-/-) mice, p53, p38, and JNK activation did not occur in response to either carcinogen. Our findings show a fundamental role of RLIP76 in chemical carcinogenesis. ©2010 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21220488      PMCID: PMC3065778          DOI: 10.1158/1535-7163.MCT-10-0699

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  49 in total

1.  Mitogenic and drug-resistance mediating effects of PKCalpha require RLIP76.

Authors:  Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Biochem Biophys Res Commun       Date:  2006-07-28       Impact factor: 3.575

2.  The role of PKCalpha and RLIP76 in transport-mediated doxorubicin-resistance in lung cancer.

Authors:  Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Kenneth Drake; Yogesh C Awasthi; Sanjay Awasthi
Journal:  FEBS Lett       Date:  2005-08-29       Impact factor: 4.124

3.  Determinants of differential doxorubicin sensitivity between SCLC and NSCLC.

Authors:  Sharad S Singhal; Dilki Wickramarachchi; Jyotsana Singhal; Sushma Yadav; Yogesh C Awasthi; Sanjay Awasthi
Journal:  FEBS Lett       Date:  2006-03-24       Impact factor: 4.124

Review 4.  Linking stress-signaling, glutathione metabolism, signaling pathways and xenobiotic transporters.

Authors:  Sushma Yadav; Ewa Zajac; Sharad S Singhal; Sanjay Awasthi
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

Review 5.  Pharmacogenetics/genomics of membrane transporters in cancer chemotherapy.

Authors:  Ying Huang
Journal:  Cancer Metastasis Rev       Date:  2007-03       Impact factor: 9.264

6.  RLIP76 is a major determinant of radiation sensitivity.

Authors:  Sanjay Awasthi; Sharad S Singhal; Sushma Yadav; Jyotsana Singhal; Kenneth Drake; Aalok Nadkar; Ewa Zajac; Dilki Wickramarachchi; Nancy Rowe; Adly Yacoub; Paul Boor; Seema Dwivedi; Paul Dent; Wendy E Jarman; Berchmans John; Yogesh C Awasthi
Journal:  Cancer Res       Date:  2005-07-15       Impact factor: 12.701

7.  RLIP76 transports vinorelbine and mediates drug resistance in non-small cell lung cancer.

Authors:  David Stuckler; Jyotsana Singhal; Sharad S Singhal; Sushma Yadav; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2005-02-01       Impact factor: 12.701

8.  Regression of lung and colon cancer xenografts by depleting or inhibiting RLIP76 (Ral-binding protein 1).

Authors:  Sharad S Singhal; Jyotsana Singhal; Sushma Yadav; Seema Dwivedi; Paul J Boor; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2007-05-01       Impact factor: 12.701

Review 9.  RLIP76: a versatile transporter and an emerging target for cancer therapy.

Authors:  Rit Vatsyayan; Poorna Chandra Rao Lelsani; Sanjay Awasthi; Sharad S Singhal
Journal:  Biochem Pharmacol       Date:  2010-01-25       Impact factor: 5.858

10.  Regression of melanoma in a murine model by RLIP76 depletion.

Authors:  Sharad S Singhal; Yogesh C Awasthi; Sanjay Awasthi
Journal:  Cancer Res       Date:  2006-02-15       Impact factor: 12.701

View more
  38 in total

1.  Didymin induces apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma.

Authors:  Jyotsana Singhal; Lokesh Dalasanur Nagaprashantha; Rit Vatsyayan; Sanjay Awasthi; Sharad S Singhal
Journal:  Cancer Prev Res (Phila)       Date:  2011-12-15

Review 2.  Antioxidant role of glutathione S-transferases: 4-Hydroxynonenal, a key molecule in stress-mediated signaling.

Authors:  Sharad S Singhal; Sharda P Singh; Preeti Singhal; David Horne; Jyotsana Singhal; Sanjay Awasthi
Journal:  Toxicol Appl Pharmacol       Date:  2015-10-23       Impact factor: 4.219

3.  RLIP76 protein knockdown attenuates obesity due to a high-fat diet.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Marpadga A Reddy; Xueli Liu; David Berz; Rama Natarajan; Sanjay Awasthi
Journal:  J Biol Chem       Date:  2013-07-02       Impact factor: 5.157

4.  Targeting RLIP with CRISPR/Cas9 controls tumor growth.

Authors:  Jyotsana Singhal; Shireen Chikara; David Horne; Sanjay Awasthi; Ravi Salgia; Sharad S Singhal
Journal:  Carcinogenesis       Date:  2021-02-11       Impact factor: 4.944

Review 5.  Novel anti-cancer compounds for developing combinatorial therapies to target anoikis-resistant tumors.

Authors:  Lokesh Nagaprashantha; Neha Vartak; Sangeeta Awasthi; Sanjay Awasthi; Sharad S Singhal
Journal:  Pharm Res       Date:  2011-12-28       Impact factor: 4.200

Review 6.  Regulatory roles of glutathione-S-transferases and 4-hydroxynonenal in stress-mediated signaling and toxicity.

Authors:  Yogesh C Awasthi; Kota V Ramana; Pankaj Chaudhary; Satish K Srivastava; Sanjay Awasthi
Journal:  Free Radic Biol Med       Date:  2016-10-26       Impact factor: 7.376

7.  P300 regulates the human RLIP76 promoter activity and gene expression.

Authors:  Archana Sehrawat; Sushma Yadav; Yogesh C Awasthi; Alakananda Basu; Charles Warden; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-02-16       Impact factor: 5.858

8.  Oncolytic adenovirus-mediated short hairpin RNA targeting MYCN gene induces apoptosis by upregulating RKIP in neuroblastoma.

Authors:  Yuan Li; Hongwei Zhang; Xiaoyu Zhu; Dongchuan Feng; Deyong Zhang; Baobiao Zhuo; Junnian Zheng
Journal:  Tumour Biol       Date:  2015-03-04

9.  Novel compound 1,3-bis (3,5-dichlorophenyl) urea inhibits lung cancer progression.

Authors:  Sharad S Singhal; James Figarola; Jyotsana Singhal; Lokesh Nagaprashantha; David Berz; Samuel Rahbar; Sanjay Awasthi
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

10.  RALBP1/RLIP76 depletion in mice suppresses tumor growth by inhibiting tumor neovascularization.

Authors:  Seunghyung Lee; Jeremy G T Wurtzel; Sharad S Singhal; Sanjay Awasthi; Lawrence E Goldfinger
Journal:  Cancer Res       Date:  2012-08-17       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.